Latest publication updates 
Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey.
(0)Del Barrio-Tofiño E1, Sánchez-Diener I1, Zamorano L1, Cortes-Lara S1, López-Causapé C1, Cabot G1, Bou G2, Martínez-Martínez L3, Oliver A1; GEMARA-SEIMC/REIPI. 1Servicio de Microbiología and Unidad de Investigación, Hospital Son Espases, Instituto de Investigación Sanitaria de les Illes Balears (IdISBa), Palma de Mallorca, Spain. 2Servicio de Microbiología, Hospital Universitario La Coruña, Instituto Investigación Biomédica A Coruña… Read More ›
Weighting the impact of virulence on the outcome of Pseudomonas aeruginosa bloodstream infections.
Sánchez-Diener I1, Zamorano L2, Peña C3, Ocampo-Sosa A4, Cabot G1, Gómez-Zorrilla S5, Almirante B6, Aguilar M7, Granados A8, Calbo E9, Baño JR10, Rodríguez-López F11, Tubau F12, Martínez-Martínez L11, Navas A13, and Oliver A14. 1Servicio de Microbiología and Unidad de Investigación, Hospital Son Espases, Instituto de Investigación Sanitaria de les Illes Balears (IdISBa), Palma de Mallorca,… Read More ›
Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology.
Del Barrio-Tofiño E1, Zamorano L1, Cortés-Lara S1, Sánchez-Diener I1, Cabot G1, Bou G2, Martínez-Martínez L3 and Oliver A1; GEMARA-SEIMC/REIPI Pseudomonas study group 1Hospital Universitario Son Espases,Palma de Mallorca,Spain. 2Servicio de Microbiología, Hospital Universitario La Coruña, Instituto Investigación Biomédica A Coruña (INIBIC), La Coruña, España. 3Unidad de Gestión Clínica de Microbiología, Hospital Reina Sofía, Departamento de… Read More ›
O-antigen serotyping and MALDI-TOF, potentially useful tools for optimizing semi-empiric antipseudomonal treatments through the early detection of high-risk clones.
Mulet X1, García R1, Gayá M1, and Oliver A1 1Hospital Universitario Son Espases,Palma de Mallorca,Spain. Abstract: The increasing prevalence of extensively drug-resistant (XDR) Pseudomonas aeruginosa infections is due to the global spread of defined high-risk clones (HRC). Among them, ST175 is particularly frequent in Spain and France. Here, we evaluated O-antigen serotyping and MALDI-TOF as… Read More ›
Interplay between Peptidoglycan Biology and Virulence in Gram-Negative Pathogens.
Juan C1, Torrens G1, Barceló IM1, Oliver A1 1Hospital Universitario Son Espases,Palma de Mallorca,Spain. The clinical and epidemiological threat of the growing antimicrobial resistance in Gram-negative pathogens, particularly for β-lactams, the most frequently used and relevant antibiotics, urges research to find new therapeutic weapons to combat the infections caused by these microorganisms. An essential previous… Read More ›
Deciphering β-lactamase-independent β-lactam resistance evolution trajectories in Pseudomonas aeruginosa.
Cabot G1, Florit-Mendoza L1, Sánchez-Diener I1, Zamorano L1, Oliver A1 1Hospital Universitario Son Espases,Palma de Mallorca,Spain. Background:While resistance related to the expression of β-lactamases, such as AmpC from Pseudomonas aeruginosa, has been deeply studied, this work addresses the gap in the knowledge of other potential bacterial strategies to overcome the activity of β-lactams when β-lactamases… Read More ›
Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae.
Scheuerman O1, Schechner V1, Carmeli Y1, Gutiérrez-Gutiérrez B2, Calbo E3, Almirante B4, Viale PL5, Oliver A6, Ruiz-Garbajosa P7, Gasch O8Gozalo M9, Pitout J10, Akova M11, Peña C12, Molina J13, Hernández-Torres A14, Venditti M15, Prim N16, Origüen J17, Bou G18, Tacconelli E19, Tumbarello M20, Hamprecht A21, Karaiskos I22, de la Calle C23, Pérez F24, Schwaber MJ1,… Read More ›
Optimization of a meropenem plus tobramycin combination dosage regimen against hypermutable and non-hypermutable Pseudomonas aeruginosa via mechanism-based modeling and the hollow-fiber infection model.
Landersdorfer CB1,2, Rees VE3,2, Yadav R3, Rogers KE3,2, Kim TH4, Bergen PJ2, Cheah SE3, Boyce JD5, Peleg AY5,6, Oliver A7, Shin BS4, Nation RL3, Bulitta JB8. 1 Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia cornelia.landersdorfer@monash.edu. 2 Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash… Read More ›
Evolution of the Pseudomonas aeruginosa aminoglycoside mutational resistome in vitro and in the cystic fibrosis setting.
López-Causapé C1, Rubio R2, Cabot G2, Oliver A2. 1 Servicio de Microbiología and Unidad de Investigación, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria de las Islas Baleares (IdISBa), Palma de Mallorca, Spain. carla.lopez@ssib.es. 2 Servicio de Microbiología and Unidad de Investigación, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria de las Islas Baleares (IdISBa),… Read More ›
Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy.
Mensa J1, Barberán J2, Soriano A1, Llinares P3, Marco F4, Cantón R5, Bou G6, González Del Castillo J7, Maseda E8, Azanza JR9, Pasquau J10, García-Vidal C1, Reguera JM11, Sousa D3, Gómez J12, Montejo M13, Borges M14, Torres A15, Alvarez-Lerma F16, Salavert M17, Zaragoza R18, Oliver A19. 1Servicio de Enfermedades Infecciosas, Hospital Clinic, Barcelona, Spain 2Servicio… Read More ›
